PE20170302A1 - Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington - Google Patents
Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntingtonInfo
- Publication number
- PE20170302A1 PE20170302A1 PE2016002253A PE2016002253A PE20170302A1 PE 20170302 A1 PE20170302 A1 PE 20170302A1 PE 2016002253 A PE2016002253 A PE 2016002253A PE 2016002253 A PE2016002253 A PE 2016002253A PE 20170302 A1 PE20170302 A1 PE 20170302A1
- Authority
- PE
- Peru
- Prior art keywords
- pridopidine
- treatment
- high doses
- huntington disease
- huntington
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Abstract
Se refiere a un metodo de tratamiento de un paciente humano afectado con enfermedad de Huntington que comprende la administracion periodica via oral de una composicion farmaceutica que comprende pridopidina o una sal farmaceuticamente aceptable de la misma, tal como clorhidrato; de tal manera que se administren mas de 135 mg de pridopidina al paciente al dia
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361837928P | 2013-06-21 | 2013-06-21 | |
US201361877832P | 2013-09-13 | 2013-09-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20170302A1 true PE20170302A1 (es) | 2017-03-31 |
Family
ID=52105289
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2015002618A PE20160195A1 (es) | 2013-06-21 | 2014-06-19 | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington |
PE2016002253A PE20170302A1 (es) | 2013-06-21 | 2014-06-19 | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2015002618A PE20160195A1 (es) | 2013-06-21 | 2014-06-19 | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington |
Country Status (24)
Country | Link |
---|---|
US (1) | US10322119B2 (es) |
EP (1) | EP3010506B1 (es) |
JP (1) | JP2016523862A (es) |
KR (1) | KR102316933B1 (es) |
CN (1) | CN105592848A (es) |
AU (1) | AU2014281414A1 (es) |
BR (1) | BR112015029918A2 (es) |
CA (1) | CA2913781C (es) |
CL (1) | CL2015003690A1 (es) |
DK (1) | DK3010506T3 (es) |
EA (1) | EA201690069A1 (es) |
ES (1) | ES2879631T3 (es) |
HK (1) | HK1221646A1 (es) |
HU (1) | HUE054783T2 (es) |
IL (1) | IL242804B (es) |
MX (1) | MX2015017307A (es) |
PE (2) | PE20160195A1 (es) |
PH (1) | PH12015502691A1 (es) |
PL (1) | PL3010506T3 (es) |
SG (1) | SG11201509729YA (es) |
TW (1) | TW201529069A (es) |
UA (1) | UA122999C2 (es) |
UY (1) | UY35624A (es) |
WO (1) | WO2014205229A1 (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
CA2810092A1 (en) | 2010-09-03 | 2012-03-08 | IVAX International GmbH | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
US9012476B2 (en) | 2011-12-08 | 2015-04-21 | IVAX International GmbH | Hydrobromide salt of pridopidine |
US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
US20150202302A1 (en) * | 2014-01-22 | 2015-07-23 | IVAX International GmbH | Modified release formulations of pridopidine |
TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
WO2016106142A1 (en) | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
HUE060353T2 (hu) * | 2015-02-25 | 2023-02-28 | Prilenia Neurotherapeutics Ltd | Pridopidin alkalmazása memória javítására |
US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
CA2993183A1 (en) * | 2015-07-22 | 2017-01-26 | Teva Pharmaceuticals International Gmbh | Pridopidine base formulations and their use |
AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
US11738012B2 (en) | 2016-02-24 | 2023-08-29 | Prilenia Neurotherapeutics Ltd. | Treatment of neurodegenerative eye disease using pridopidine |
EP3504187A4 (en) * | 2016-08-24 | 2020-05-06 | Prilenia Neurotherapeutics Ltd. | USE OF PRIDOPIDINE FOR THE TREATMENT OF FUNCTIONAL DECLINE |
MX2019002190A (es) * | 2016-08-24 | 2019-09-11 | Prilenia Therapeutics Dev Ltd | Uso de pridopidina para tratar distonías. |
WO2018053287A1 (en) * | 2016-09-15 | 2018-03-22 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for the treatment of anxiety and depression |
CA3036984C (en) | 2016-09-16 | 2023-07-18 | Prilenia Therapeutics Development Ltd. | Use of pridopidine for treating rett syndrome |
CN110505902B (zh) | 2017-01-20 | 2022-11-11 | 普瑞尼亚神经治疗有限公司 | 普利多匹定用于治疗脆性x综合征的应用 |
EP3668509B1 (en) | 2017-08-14 | 2022-11-16 | Prilenia Neurotherapeutics Ltd. | Method of treating amyotrophic lateral sclerosis with pridopidine |
CA3073568A1 (en) | 2017-08-30 | 2019-03-07 | Prilenia Neurotherapeutics Ltd. | High concentration dosage forms of pridopidine |
CN111343982A (zh) | 2017-09-08 | 2020-06-26 | 普瑞尼亚神经治疗有限公司 | 用于治疗药物诱发的异动症的普利多匹定 |
WO2020250234A1 (en) * | 2019-06-12 | 2020-12-17 | Prilenia Neurotherapeutics Ltd. | Composition comprising pridopidine and analog thereof for treating huntington disease and symptoms thereof |
WO2021055443A1 (en) * | 2019-09-17 | 2021-03-25 | Hoffmann-La Roche Inc. | Improvements in personalized healthcare for patients with movement disorders |
US20230390232A1 (en) * | 2020-10-28 | 2023-12-07 | Buck Institute For Research On Aging | N-propargylglycine: a unique inhibitor of proline dehydrogenase with brain-enhancing mitohormesis properties capable of mitigating the pathogenesis of neurodegenerative disorders |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
EP1713486A4 (en) | 2003-12-02 | 2009-04-29 | Sheldon Leslie James | COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY |
WO2006040155A1 (en) | 2004-10-13 | 2006-04-20 | Neurosearch Sweden Ab | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine |
EP1815857A1 (en) * | 2006-02-02 | 2007-08-08 | LEK Pharmaceuticals D.D. | A pharmaceutical composition comprising perindopril |
PT2146961E (pt) | 2007-04-12 | 2014-04-30 | Ivax Int Gmbh | Derivados de n-óxido e/ou di-n-óxido de estabilizadores / moduladores dos recetores da dopamina exibindo perfis de efeitos secundários cardiovasculares melhorados |
WO2010008486A2 (en) | 2008-06-24 | 2010-01-21 | Parkinsons Institute | Pluripotent cell lines and methods of use thereof |
US8384755B2 (en) | 2009-08-26 | 2013-02-26 | Intouch Technologies, Inc. | Portable remote presence robot |
US20110206782A1 (en) * | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of dopamine receptor |
WO2011107583A1 (en) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
CA2810092A1 (en) | 2010-09-03 | 2012-03-08 | IVAX International GmbH | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
EA023462B1 (ru) | 2011-09-07 | 2016-06-30 | Тева Фармасьютикалз Интернэшнл Гмбх | Полиморфная форма гидрохлорида придопидина |
US9012476B2 (en) | 2011-12-08 | 2015-04-21 | IVAX International GmbH | Hydrobromide salt of pridopidine |
US9744155B2 (en) | 2012-03-28 | 2017-08-29 | Ixcela, Inc. | IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk |
CA2869145A1 (en) | 2012-04-04 | 2013-10-10 | IVAX International GmbH | Pharmaceutical compositions for combination therapy |
EP2900226A4 (en) | 2012-09-27 | 2016-03-30 | Teva Pharma | COMBINATION OF RASAGILIN AND PRIDOPIDIN FOR TREATING NEURODEGENERATIVE DISORDERS, ESPECIALLY HUNTINGTON'S DISEASE |
US20140088140A1 (en) | 2012-09-27 | 2014-03-27 | Teva Pharmaceutical Industries, Ltd. | Combination of laquinimod and pridopidine for treating neurodegenerative disorders, in particular huntington's disease |
US20150202302A1 (en) | 2014-01-22 | 2015-07-23 | IVAX International GmbH | Modified release formulations of pridopidine |
TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
WO2016106142A1 (en) | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
HUE060353T2 (hu) | 2015-02-25 | 2023-02-28 | Prilenia Neurotherapeutics Ltd | Pridopidin alkalmazása memória javítására |
WO2016138135A1 (en) | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Sigma-1 receptor modulators for treating huntington's disease |
AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
CA2993183A1 (en) | 2015-07-22 | 2017-01-26 | Teva Pharmaceuticals International Gmbh | Pridopidine base formulations and their use |
WO2017048457A1 (en) | 2015-09-18 | 2017-03-23 | Teva Pharmaceuticals Industries Ltd. | Combination of laquinimod and pridopidine to treat multiple sclerosis |
MX2019002190A (es) | 2016-08-24 | 2019-09-11 | Prilenia Therapeutics Dev Ltd | Uso de pridopidina para tratar distonías. |
EP3504187A4 (en) | 2016-08-24 | 2020-05-06 | Prilenia Neurotherapeutics Ltd. | USE OF PRIDOPIDINE FOR THE TREATMENT OF FUNCTIONAL DECLINE |
WO2018053287A1 (en) | 2016-09-15 | 2018-03-22 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for the treatment of anxiety and depression |
CA3036984C (en) | 2016-09-16 | 2023-07-18 | Prilenia Therapeutics Development Ltd. | Use of pridopidine for treating rett syndrome |
WO2018053275A1 (en) | 2016-09-16 | 2018-03-22 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for the treatment of familial dysautonomia |
-
2014
- 2014-06-19 KR KR1020167001531A patent/KR102316933B1/ko active IP Right Grant
- 2014-06-19 ES ES14813621T patent/ES2879631T3/es active Active
- 2014-06-19 EP EP14813621.1A patent/EP3010506B1/en active Active
- 2014-06-19 SG SG11201509729YA patent/SG11201509729YA/en unknown
- 2014-06-19 UA UAA201600462A patent/UA122999C2/uk unknown
- 2014-06-19 PE PE2015002618A patent/PE20160195A1/es not_active Application Discontinuation
- 2014-06-19 DK DK14813621.1T patent/DK3010506T3/da active
- 2014-06-19 JP JP2016521580A patent/JP2016523862A/ja not_active Withdrawn
- 2014-06-19 US US14/309,111 patent/US10322119B2/en active Active
- 2014-06-19 CN CN201480035525.7A patent/CN105592848A/zh active Pending
- 2014-06-19 PE PE2016002253A patent/PE20170302A1/es not_active Application Discontinuation
- 2014-06-19 EA EA201690069A patent/EA201690069A1/ru unknown
- 2014-06-19 CA CA2913781A patent/CA2913781C/en active Active
- 2014-06-19 WO PCT/US2014/043204 patent/WO2014205229A1/en active Application Filing
- 2014-06-19 HU HUE14813621A patent/HUE054783T2/hu unknown
- 2014-06-19 PL PL14813621T patent/PL3010506T3/pl unknown
- 2014-06-19 MX MX2015017307A patent/MX2015017307A/es unknown
- 2014-06-19 AU AU2014281414A patent/AU2014281414A1/en not_active Abandoned
- 2014-06-19 BR BR112015029918A patent/BR112015029918A2/pt not_active Application Discontinuation
- 2014-06-20 TW TW103121433A patent/TW201529069A/zh unknown
- 2014-06-23 UY UY35624A patent/UY35624A/es not_active Application Discontinuation
-
2015
- 2015-11-26 IL IL242804A patent/IL242804B/en unknown
- 2015-12-02 PH PH12015502691A patent/PH12015502691A1/en unknown
- 2015-12-21 CL CL2015003690A patent/CL2015003690A1/es unknown
-
2016
- 2016-08-16 HK HK16109788.9A patent/HK1221646A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
PL3010506T3 (pl) | 2021-11-02 |
PE20160195A1 (es) | 2016-05-14 |
CA2913781A1 (en) | 2014-12-24 |
SG11201509729YA (en) | 2015-12-30 |
US10322119B2 (en) | 2019-06-18 |
HK1221646A1 (zh) | 2017-06-09 |
ES2879631T3 (es) | 2021-11-22 |
WO2014205229A8 (en) | 2015-04-09 |
UA122999C2 (uk) | 2021-02-03 |
KR20160055122A (ko) | 2016-05-17 |
CL2015003690A1 (es) | 2016-10-28 |
BR112015029918A2 (pt) | 2017-07-25 |
PH12015502691A1 (en) | 2016-03-14 |
EP3010506A4 (en) | 2017-02-08 |
WO2014205229A1 (en) | 2014-12-24 |
CA2913781C (en) | 2022-05-10 |
JP2016523862A (ja) | 2016-08-12 |
DK3010506T3 (da) | 2021-07-12 |
TW201529069A (zh) | 2015-08-01 |
IL242804B (en) | 2022-02-01 |
MX2015017307A (es) | 2016-08-03 |
AU2014281414A1 (en) | 2016-01-21 |
EP3010506A1 (en) | 2016-04-27 |
UY35624A (es) | 2015-01-30 |
EA201690069A1 (ru) | 2016-06-30 |
KR102316933B1 (ko) | 2021-10-26 |
EP3010506B1 (en) | 2021-05-12 |
CN105592848A (zh) | 2016-05-18 |
HUE054783T2 (hu) | 2021-09-28 |
US20140378508A1 (en) | 2014-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20170302A1 (es) | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington | |
CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
CL2016001874A1 (es) | Forma de dosificación oral sólida de liberación modificada que comprende pridopidina y un excipiente de control de velocidad; formulación farmacéutica que comprende a la forma de dosificación; uso de la forma de dosificación o de la formulación farmacéutica para tratar una enfermedad neurodegenerativa o relacionada con dopamina, como la enfermedad de huntington, entre otras. | |
PE20150161A1 (es) | Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple | |
BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
NI201100147A (es) | Métodos para tratar infartos agudos de miocardio y trastornos relacionados. | |
UA106636C2 (uk) | Морфолінотіазоли як позитивні алостеричні модулятори альфа 7 | |
MX2022003072A (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
PE20181332A1 (es) | Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos | |
JP2015532296A5 (es) | ||
CL2013002810A1 (es) | Composicion farmaceutica solida oral que comprende a) un compuesto 2-amino-2-[2-(4-octil-fenil)-etil]-propano-1,3-diol (fingolimod) en una cantidad de 0,5 mg o menos, o una sal del mismo, b) un relleno y c) un estabilizante que comprende una ciclodextrina; y su uso para tratar una enfermedad autoinmune tal como esclerosis multiple. | |
NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
CL2012003152A1 (es) | Composicion farmaceutica para ser usada en terapia de reemplazo de glucocorticoides mediante la administracion oral una vez al dia de una dosis equivalente a la hidrocortizona de acuerdo con un nomograma de peso o un nomograma farmacocinetico; metodo de tratamiento; metodo para derivar una dosificacion individualizada. | |
MX2022015629A (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
AR098832A1 (es) | Uso de laquinimod para retrasar la progresión de la enfermedad de huntington | |
AR079000A1 (es) | Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas | |
MX341660B (es) | Agonista del receptor de ghrelina para el tratamiento de caquexia. | |
BR112014004339A2 (pt) | suspensão oral | |
BR112014030288A8 (pt) | composição farmacêutica, uso da mesma, e, uso de metanossulfonilacetonitrila | |
AR074246A1 (es) | Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno | |
EA201592261A1 (ru) | Фармацевтические композиции, включающие агомелатин в форме сокристаллов агомелатина с органической кислотой | |
BR112015028581A2 (pt) | composição farmacêutica de dosagem baixa, utilização do ácido, método para o tratamento da doença inflamatória e composição farmacêutica | |
AR114012A1 (es) | Método para proporcionar terapia de celiprolol a un paciente | |
RU2013128858A (ru) | Способ лечения кариеса зубов |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |